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A liquid-liquid extraction (LLE) combined with high-performance liquid chromatography-diode array 
detection method for simultaneous analysis of four chemically and structurally different antineoplastic 
drugs (cyclophosphamide, doxorubicin, 5-fluorouracil and ifosfamide) was developed. The assay was 
performed by isocratic elution, with a C18 column (5 µm, 250 x 4.6 mm) and mobile phase constituted 
by water pH 4.0- acetonitrile-methanol (68:19:13, v/v/v), which allowed satisfactory separation of the 
compounds of interest. LLE, with ethyl acetate, was used for sample clean-up with recoveries ranging 
from 60 to 98%. The linear ranges were from 0.5 to 100 µg mL-1, for doxorubicin and 1 to 100 µg mL-1, 
for the other compounds. The relative standard deviations ranged from 5.5 to 17.7%. This method is 
a fast and simple alternative that can be used, simultaneously, for the determination of the four drugs 
in plasma, with a range enabling quantification of the drugs in pharmacokinetics, bioequivalence and 
therapeutic drug-monitoring studies.
Uniterms: Antineoplastic drugs/simultaneous determination in plasma. Liquid-liquid extraction. High-
performance liquid chromatography/diode array detector.
Um método de extração líquido-líquido (ELL) combinado com cromatografia líquida de alta eficiência-
detector de arranjo de diodos foi desenvolvido para análise simultânea de quatro fármacos antineoplásicos 
quimicamente e estruturalmente diferentes (ciclofosfamida, doxorrubicina, fluoruracila e ifosfamida). 
O estudo foi realizado sob condições isocráticas, com coluna C18 (5µm, 250 x 4.6 mm) e fase móvel 
constituída por água pH 4.0-acetonitrila-metanol (68:19:13, v/v/v), que permitiu separação satisfatória 
dos analitos de interesse. A ELL, com acetato de etila, foi utilizada para limpeza da amostra, com 
recuperação variando de 60 a 98%. As faixas foram lineares de 0,5 a 100 µg mL-1 para doxorrubicina e 
1 a 100 µg mL-1 para os outros compostos. O desvio padrão relativo variou de 5,5 a 17,7%. Este método 
é uma alternativa rápida e simples que pode ser usado, simultaneamente, para a determinação dos 
quatro fármacos em plasma, com uma faixa que permite quantificá-los em estudos de farmacocinética, 
bioequivalência e monitorização terapêutica.
Unitermos: Fármacos antineoplásicos/determinação simultânea em plasma. Extração líquido-líquido. 
Cromatografia líquida de alta eficiência/detector de arranjo de diodos.
INTRODUCTION
Antineoplastic agents are drugs used in chemothe-
rapy which are not selective for cancer cells since they 
also affect the growth and reproduction of healthy cells. 
According to the International Agency for Research on 
Cancer (IARC), at least nine alkylating cytostatic drugs 
are classified as carcinogenic to humans (Group 1). In 
addition, several drugs are classified by the IARC into 
Groups 2A and 2B (probably and possibly carcinogenic to 
humans, respectively). The optimal dose should produce a 
maximal anti-tumor effect with acceptable levels of toxici-
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ty. In clinical practice, these drugs frequently cause toxic 
effects that would be considered unacceptable. Although 
toxicity is commonly regarded as the most important effect 
to control, partly because it is easier to measure, the risk 
of under-dosing and reduced efficacy must also be con-
sidered. In most of the current chemotherapy protocols, 
antineoplastics are used as a combination of agents having 
different mechanisms of action in order to decrease the 
dose of each agent individually thus keeping the synergism 
of therapeutic effects and minimizing the toxic effects 
(Turci et al., 2003)
Combination chemotherapy is administered in order 
to target as many types of cells in the tumor as possible. 
Selection of agents for combination chemotherapy regi-
mens involves consideration of drug-specific factors such 
as mechanism of action, antitumor activity, and toxicity 
profile. Drugs that possess minimally overlapping mecha-
nisms of action and toxicities are combined when possible 
(Kamil et al., 2010).
Nevertheless, as a consequence, patients may be 
exposed to a wide variety of substances and few methods 
have been described for the simultaneous determination 
of these drugs in plasma (Roberts et al., 2006; Turci et 
al., 2002; Kaestner, Sewell, 2007). In the present study, a 
single method was developed to determine four substances 
with toxicological significance in plasma.
Cyclophosphamide (CP), 2-bis(2-chloroethyl) 
aminotetrahydro-2H-1,3,2-oxazophosphorine-2-oxide, is 
one of the most commonly used antineoplastic alkylating 
agents. It has also been used due to its immunosuppressi-
ve properties in the treatment of autoimmune diseases as 
well as in renal and bone marrow transplants. CP has been 
classified as a human carcinogen (Group 1) by the IARC. 
Ifosfamide (IF), 3-(2-chloroethyl)-2-[(2-chloro-ethyl)
amino] tetrahydro-2H-1,3,2-oxazaphosphorin-2-oxide, is 
a structural analogue of CP having alkylating activity after 
enzymatic activation to cytotoxic compounds. IF differs 
from CP in the transfer of one 2-chloroethyl group from 
the extracyclic to the endocyclic nitrogen. This results 
in differences in pharmacological and toxicological pro-
perties. Although IF has been shown to be carcinogenic 
in animals, there is no evidence of its carcinogenicity in 
humans and it is therefore included by the IARC in Group 
3. Both cyclophosphamide and ifosfamide are widely used 
in the treatment of non-Hodgkin lymphomas and a variety 
of bone and soft tissue sarcomas. The pharmacological 
profile of these drugs is important and, in order to gather 
this information, reliable methods for the determination 
of oxazaphosphorines and their metabolites are necessary 
when determining optimal dosages (Turci et al., 2003; 
Ekhart et al., 2007; Baumann, Preiss, 2001).
Doxorubicin (DOX) is classified as an anthracycli-
ne, a glycosidic derivative of tetra-hydronaphthacene 
that belongs to the tetracycline class of antibiotics. The 
antineoplastic activity of these drugs has been mainly 
attributed to their strong interactions with DNA in target 
cells. These drugs can deform DNA structure and termi-
nate its biological function. Furthermore, they can be 
reduced to their semiquinone form by biological reducing 
agents, such NADH and NADPH. Free radicals can be 
generated, which can attack cell components, such as 
membrane and DNA, and halt cell growth. According 
to the IARC, these agents are probably carcinogenic to 
humans (Group 2A). There is inadequate evidence of 
carcinogenicity in humans, but sufficient evidence of 
carcinogenicity in animals (Turci et al., 2003; Ekhart et 
al., 2007).
The drug 5-fluorouracil (5-FU), 5-fluoropyrimidine-
2,4-dione, is an antimetabolite frequently used in the 
treatment of malignancies including cancers of the gas-
trointestinal tract, lung, and breast. It acts as a competitor 
of pyrimidine and needs to be converted to the nucleotide 
level so as to exert its effect. 5-FU is classified as Group 
3 (not classifiable as to carcinogenicity to humans) by the 
IARC based on inadequate evidence of carcinogenicity in 
humans and animals (Turci et al., 2003).
Several methods have been described in literature 
for environmental and biological monitoring of anti-
neoplastics. The majority of the papers have described 
methods employing HPLC, using various detector types. 
Antracyclines and 5-FU can be determined by HPLC 
with fluorescence and UV detection, respectively. Sample 
extracts were injected into a C18 reversed-phase column 
with a proportion of organic solvent and buffer as mobile 
phase. Determination of oxazaphosphorines in serum, 
blood or plasma has been demonstrated by using HPLC 
with detection at low UV wavelengths. The sample pre-
paration techniques commonly used involve liquid-liquid 
extraction (LLE) and solid phase extraction (SPE) (Boos et 
al., 1994; Burton, James, 1988; Hardy, Erlichman, Soldin, 
1984; Margison et al., 1986; May-Manke et al., 1999; 
Rustum, Hoffman, 1987; Sottani et al., 2005; Martins et 
al., 2009).
Since HPLC assays are inexpensive and widely 
used, they represent a good choice for the analysis of 
antineoplastic drugs. Moreover, LLE is still the sample 
preparation technique most employed and used in routine 
analysis. The purpose of this investigation was to deve-
lop a single analytical LLE-HPLC-UV method for the 
simultaneous determination of CP, IF, 5-FU and DOX in 
plasma samples.
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MATERIALS AND METHODS
Instrumental and operating conditions
The HPLC equipment consisted of a Shimadzu LC-
10ATvp (Kyoto, Japan) gradient system equipped with a 
Shimadzu SIL-10AF (Kyoto, Japan) auto-injector with 
a 50 µL loop. The column oven used was a Shimadzu 
CTO-10ASvp (Kyoto, Japan) operated at 25 ºC. Firstly, the 
detection was performed with a Shimadzu SPD-M10Avp 
(Kyoto, Japan) diode array detector and the quantification 
was performed with a Shimadzu SPD-10Avp (Kyoto, 
Japan) UV detector at 195 nm and at 265 nm. Separation 
was achieved by isocratic elution carried out with a mobile 
phase constituted of water adjusted to pH 4 (with hydro-
chloric acid)- acetonitrile- methanol (68:19:13, v/v/v), at a 
flow rate of 0.6 mL min-1 for 8 min and then 1.0 mL min-1, 
with a Shimpak CLC-ODS (250 x 4.6 mm, 5 mm) column 
protected by a similar guard-column (40 x 4.6 mm). Data 
acquisition and treatment were performed by Class-VP 
software (Shimadzu).
Standards and reagents
Cyclophosphamide (CP), 5-fluorouracil (5-FU) 
and ifosfamide (IF) were purchased from Sigma-Aldrich 
Chemical Company (St. Louis, USA); doxorubicin (DOX) 
was purchased from Fluka (Buchs, Switzerland). Aceto-
nitrile and methanol (HPLC grade) were obtained from 
Mallinckrodt® (Paris, USA). Other chemicals that were 
used include the following: hydrochloric acid, isopropyl 
alcohol, chloroform, ethyl ether and ethyl acetate from 
Vetec (Rio de Janeiro, Brazil). Water was distilled and 
purified by using a Millipore® Milli-Q Plus system (São 
Paulo, Brazil).
Standard solutions
Stock standard solutions were prepared by disso-
lution of each drug in methanol to obtain a concentration 
of 1 mg mL-1. These solutions were stored at -20 ºC and 
prepared weekly. The working solutions were prepared 
each day by making a 10-fold dilution of the stock solution 
in methanol. 
Sample preparation
Aliquots of 1.0 mL of blank plasma spiked with the 
drugs (CP, IF, DOX and 5-FU) were extracted with 5.0 mL 
of ethyl acetate. The tubes were submitted to shaking for 
15 minutes at 50 rpm and then centrifuged for 10 minutes 
at 4000 x g. The upper organic phases were transferred 
to conical tubes and separated, and the aqueous layer 
re-extracted with 5.0 mL of ethyl acetate. The organic 
phases were combined and evaporated at 40 ºC under a 
gentle stream of nitrogen. The residues were reconstituted 
in 200 µL mobile phase and 50 µL were injected into the 
HPLC system.
Confidence parameters
Validation of this study was in compliance with FDA 
guidelines (FDA, 2001). The following parameters were 
assayed: robustness, linearity, lower limit of quantification 
(LOQ), precision and recovery.
Robustness was performed at middle level 
(20 µg mL-1) and was explored using mobile phase flow 
rate and column temperature. Linearity was tested by 
examination of a plot of residues produced by linear re-
gression of the responses on the amounts of the analytes 
in a calibration set, between 1 and 100 mg mL-1, in six 
replicates for each level. A calibration curve was gener-
ated in duplicate for each analytical run and consisted of 
a blank and six non-zero samples covering the expected 
range, including LOQ.
LOQ was obtained by the successive dilutions to 
determine the lowest concentration with accuracy and 
precision, as 10% RSD (relative standard deviation), with 
a signal-to-noise ratio of 10:1.
Precision of the method was evaluated by within-day 
(n=3) assay using plasma spiked with the drugs at LOQ, 
middle and high level, during a single analytical run. The 
results obtained for precision were expressed as relative 
standard deviation (RSD %). Recovery was determined 
by five replicate analyses of samples after spiking with 
a known mass of the analyte, in the non-contaminated 
samples. The results were compared with those obtained 
when the analyte was spiked after the clean-up procedure 
of the sample. 
Method application
To assess the applicability of the validated method, 
the level of the drugs in plasma were measured after 
administration of the drugs at 10 mg/kg  in Male Wistar 
rats. The animals (n=5), weighing 300 ± 20 g, were kept 
under standardized conditions, according to institutional 
guidelines. Blood samples were collected (jugular vein 
cannulation) at 0 min, 15 min, 3, 6, 12 and 24 hours after 
intravenous administration of the drugs in saline. The 
samples were centrifuged for 15 min at 2000 x g and the 
plasma was stored at -20 ºC until analysis.
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RESULTS AND DISCUSSION
The HPLC method appears to be the most feasible 
for attaining the lower limit of detection and quantification 
when used for detection of multiple antineoplastics (Lar-
son, Khazaeli, Dillon, 2003). Since patients are exposed to 
a wide variety of drugs, it is necessary to develop methods 
able to quantify multiple agents, with a single sampling. 
Although there is a large demand for analytical methods 
that simultaneously determine various compounds in 
biological and non biological matrices, current literatu-
re presents methods for an individual agent only, or for 
chemically similar groups. In this study, the aim was to 
develop a method able to determine the presence of four 
structurally different drugs (Figure 1), extensively used in 
clinical practice, in a single analysis. This enables more 
comprehensive monitoring of the therapeutic treatment 
to be carried out.
Optimized chromatographic conditions
The diode array detector was able to analyze, simul-
taneously, the extract sample at various wavelengths. In 
fact, this property increased the selectivity of the method 
since the similarity of the peaks, in the retention time 
of the analytes (Table I), are compared with the second 
derivative spectrum, in a library developed with standard 
solutions (Figure 1).
The HPLC behavior of CP, IF, 5-FU and DOX 
extracted from human plasma was isocratically exami-
ned by using a C-18 analytical column. Several mobile 
phases were tested and it was found that water adjusted 
to pH 4- acetonitrile-methanol (68:19:13, v/v/v) at a flow 
rate of 0.6 mL min-1 for 8 min and 1.0 mL min-1 allowed 
satisfactory separation of the compounds of interest. The 
method robustness was demonstrated since the response of 
the analytes remained constant when one percent variation 
in the organic composition of the mobile phase, in the flow 
rate of mobile phase and in the column temperature was 
applied to the chromatographic conditions.
Before performing validation experiments, system 
suitability was evaluated. These tests are used to verify if 
the resolution and repeatability of the system are adequate 
for the analysis and are used for checking system perfor-
mance (Shabir, 2003).
Parameters such as plate count, tailing factors and 
resolution were determined and compared against the 
specifications, as demonstrated in Table I. It is possible to 
observe that the system was suitable since the results of 
the test were considered satisfactory, according to Shabir 
(2003), who reported an acceptable range of plate count > 
2000, resolution > 2.0, tailing factor between 0.5 and 2.0 
FIGURE 1 - Spectra and chemical structures of antineoplastic drugs:  (A) fluorouracil, (B) ifosfamide, (C) doxorubicin and (D) 
cyclophosphamide.
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TABLE I - System suitability parameters* for HPLC-UV method evaluated for simultaneous determination of fluorouracil, ifosfamide, 
cyclophosphamide and doxorubicin
Analyte Retention time (min) Plate count (N) Resolution (Rs) Tailing factor (T) Retention factor (k)
5-FU 5.0 3456 - 1.5 4
IF 15.9 27719 11.9 1.2 15
DOX 16.3 28566 0.4 1.7 17
CP 18.5 26807 2.0 1.5 16
*Reference values: N ≥ 2000; Rs ≥ 2; 0.5 ≤ T ≤  2; k > 2 (Shabir, 2003)
and k > 2 (Shabir, 2003). Although the values of resolution 
between the peaks of DOX and IF was 0.4, these analytes 
were read at different wavelengths.
Optimized sample treatment
To clean-up samples, a number of experiments 
were then conducted to optimize the extraction efficacy. 
In order to find the most efficient extraction procedure 
for the analytes studied using LLE, different conditions 
were compared.
Liquid-liquid extraction is simple and a large num-
ber of solvents, pure and commercially available, can be 
used which provide a wide range of solubility and selectiv-
ity. Furthermore, the proteins present in the samples are 
denatured, eliminating the contamination of the chromato-
graphic column (Queiroz, Collins, Jardim, 2001). Coe et 
al. (1996) reported an LLE procedure for the analysis of 
fluoruracil in plasma samples, using the pH adjustment 
to 6.0 by adding acetate buffer, followed by a saturated 
solution of sodium sulfate and 7.0 mL of ethyl acetate, 
with around 46% of recovery (Coe et al., 1996). For the 
ifosfamide and cyclophosphamide isomers, Turci et al. 
(2002) proposed an LLE for urine samples in which 5 mL 
of sample was adjusted to pH 7, then extracted three times 
with 10 mL of ethyl acetate (Turci et al., 2002). A percent-
age of 85% for both analytes was obtained. Kümmerle 
et al. (2003) proposed an LLE for DOX using 500 mL 
of biological fluid, pre-treated with a precipitation of the 
protein, then 250 mL of acetone and 50 mL of an aqueous 
solution of zinc sulfate 70% as a solvent extractor were 
added (Kümmerle et al., 2003). In our study, the principles 
of liquid-liquid extraction were optimized according to 
the following steps: type and volume of extractor solvent, 
shaking velocity, number of extractions totaling 10 mL 
and salting-out effect.
Various extractor solvents were tested alone and as a 
mixture of solvents. The response of the analytes was vari-
able, as shown in Figure 2, and a satisfactory percentage 
of recovery for the four analytes was obtained with ethyl 
acetate. This solvent was the same used in the method of 
extraction by Turci et al. and Coe et al. for the analytes 
ifosfamide and cyclophosphamide, and 5-fluorouracil, 
respectively (Coe et al., 1996; Turci et al., 2002). The 
volume of the solvent of 10 mL (Figure 2) was consid-
ered optimum since a balance between the efficiency of 
the extraction and the environmental implications were 
considered in the present study.
Shaking velocity was tested at speeds of 50 and 
70 rpm in an automatic horizontal shaker. As demonstrated 
in Figure 2, with the rate of 70 rpm a slightly higher percen-
tage of recovery was observed, but this speed caused sig-
nificant solvent extractor loss and increased interference in 
the extract. Thus, the 50 rpm rate was considered optimum.
If a component has a low coefficient of distribution 
between an organic solvent and water, one or more simple 
extractions will not remove a lot of the components from 
the water. This distribution coefficient can be changed 
by adding salt to water. Sometimes, the difference in 
solubility is dramatic, since organic compounds are more 
soluble in pure water than in water with salt. Thus, a simple 
dissolution of salt in the aqueous layer can increase the 
distribution of an organic compound in an organic solvent; 
an effect commonly known as salting-out (Queiroz et al., 
1995). In the present study the following salts were tested: 
NaCl, Na2SO4 and (NH4)2SO4. However, the addition of 
salt did not increase the percentage of recovery.
The solid phase extraction was also assessed in order 
to obtain a selective separation, purification and concen-
tration of compounds present in the complex matrices. 
According to the literature (Baumann et al., 1999; Micoli 
et al., 2001; Minoia, Perbelini, 2000), the initial sorbent 
tested was octadecilsilane (C18) in a cartridge. However, 
it was not possible to optimize a condition to allow the 
simultaneous extraction of the four analytes, with a sa-
tisfactory percentage of recovery. Therefore, the styrene/
divinylbenzene copolymer as sorbent was tested, under 
different conditions for steps of conditioning, sample pH, 
washing and elution. But again, these tests did not result 
in an optimum condition for the agents studied. This 
A. L. Sanson, S. C. R. Silva, M. C. G. Martins, A. Giusti-Paiva, P. P. Maia, I. Martins368
FIGURE 2 - Results expressed as extraction efficiency (%) of fluorouracil (5-FU), ifosfamide (IF), cyclophosphamide (CP) and 
doxorubicin (DOX), in the LLE studies of type (A) and solvent extractor volume (B), shaking velocity (C) and number of extractions 
totaling 10 mL (D).
negative result can be explained by the different physico-
chemical characteristics of anticancer substances, such 
as solubility and pKa, factors that interfere with the SPE. 
Finally, silica and florisil, home-made cartridges, were 
tested in the matrix clean-up. These tests also produced 
no satisfactory results. Therefore, LLE was applied in the 
plasma samples and in Figure 3, it is possible to observe 
FIGURE 3 - Typical HPLC chromatograms, under optimal 
conditions evaluated: 20 µg mL-1 of fluoruracil (5-FU), 
ifosfamide (IF), doxorubicin (DOX) and cyclophosphamide 
(CP) extracted from plasma samples.
the typical chromatograms of extracted plasma samples 
at a fortification level of 20 µg mL-1 for IF, CF, 5-FU and 
DOX by using the optimized HPLC conditions.
Confidence parameters
Calibration curves were obtained by plotting the 
peak area and resulted in a linear response over the range 
studied. The results of the linearity test are presented 
in Table II. The calibration curves were linear from 
1-100 µg mL-1.
The method was linear in the range of 1 mg mL-1 to 
100 mg mL-1 for the drugs 5-FU, IF and CF. For doxoru-
bicin, the method was linear in the concentration range of 
0.5 mg mL-1 to 100 mg mL-1. The sensitivity of the method, 
assessed by the value of the slope, shows that for IF, CF 
and DOX the method provides similar sensitivity. For 
5-FU, the method demonstrated a higher sensitivity, since 
the value of the slope for this analyte is about 20 times 
larger compared to other compounds studied.
The LOQ value was 1 mg mL-1 for the analytes, 
except for DOX that was 0.5 mg mL-1. Thus, with these 
values it is possible to quantify the analytes in plasma 
samples (Table III) after a therapeutic dose (Goodman, 
Gilman, 2006). The results are in agreement with the 
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TABLE II - Analytical curve parameters for simultaneous determination of fluorouracil (5-FU), ifosfamide (IF), doxorubicin (DOX) 
and cyclophosphamide (CP) by HPLC-DAD-UV
Parameters 5-FU IF DOX CP
Range (µg mL-1)
Correlation coefficient (r)
Slope
Intercept 
1- 100 
0.992
633472
20300
1-100
0.995
31722
67466
0.5-100 
0.998
38117
42577
1-100
0.991
30413
-14040
TABLE III - Mean plasmatic concentration of 5-fluorouracil (5-FU), 
ifosfamide (IF), doxorubicin (DOX) and cyclophosphamide 
(CP), according to Goodman & Gilman, 2006.
Drug Mean plasmatic concentration
5-FU
IF
DOX
CP 
Intravenous administration: 46 μg mL-1
Intravenous administration: 53.0 μg mL-1
Oral administration: 52.2 μg mL-1
Intravenous administration: 33.7 μg mL-1
Intravenous administration: 0.49 μg mL-1
TABLE IV - Precision and recovery of the method for 
simultaneous analysis of fluorouracil (5-FU), ifosfamide (IF), 
doxorubicin (DOX) and cyclophosphamide (CP) by LLE- 
HPLC-UV in plasma 
Level (µg mL-1)
1 20 100
5-FU
RSD % 13.4 11.3 5.7
recovery (%) 74 85 91
IF
intra-assay (RSD%) 17.7 5.5 9.8
recovery (%) 91 93 96
DOX
intra-assay (RSD%) 17.6 14.1 8.6
recovery (%) 81 88 97
CP
intra-assay (RSD%) 8.6 12.5 7.5
recovery (%) 60 90 98
study conducted by Martins et al. 2009 that evaluated a 
range of 1- 150 mg mL-1, for simultaneous determination 
of IF and CP.
The repeatability of the optimized method was cal-
culated by the relative standard deviation (RSD%) and 
was expressed as the following equation: RSD%= (SD/
mean measured concentration) x 100, and SD is the stan-
dard deviation (Table IV). The efficiency of the extraction 
obtained after the optimized LLE was satisfactory for the 
drugs studied, as summarized in Table IV.
Recoveries near 100% were in compliance with 
the FDA guide (FDA, 2001). The results obtained with 
the optimized LLE can be considered satisfactory since 
the method was precise and accurate. The results were 
compared with those in the literature, such as the study 
of Coe et al. (1996) that obtained, for 5-FU, an average 
recovery of 46% and Turci et al. (2002), that reported a 
recovery of 85% for IF and CF in urine, but using a total 
volume of 30 mL of solvent extractor (Coe et al., 1996; 
Turci et al., 2002).
Method application
In order to demonstrate the applicability of the va-
lidated method the drugs were administered to rats. First, 
a calibration curve for each drug was obtained by adding 
5-FU, IF and CP to aliquots of a pool of plasma of rats 
at concentrations of 1, 20 and 100 µg mL-1, and DOX at 
concentrations of 0.5, 20 and 100 µg mL-1. These samples 
were submitted to the method, then the signals obtained 
were plotted to obtain the analytical curves and linearity 
values. To check the influence of the matrix, a correlation 
test was performed comparing the standard curves obtai-
ned for each analyte in human plasma to curves obtained 
in plasma from rats. A correlation between the curves 
(r>0.85) was observed, confirming that the method vali-
dated in human plasma can be used for plasma of animals.
The samples were obtained through the adminis-
tration of a single intravenous infusion (2 mL) of saline 
containing antineoplastic agents studied in therapeutic 
concentration. We also obtained a sample blank by injec-
ting only 2 mL of saline without drugs. The blood samples 
were then collected at the timepoints of 15 minutes, 3, 
6, 12 and 24 hours after the infusion. After separation of 
plasma, it was submitted to the optimized LLE and the data 
were used to obtain the kinetic curve of each drug. In Fi-
gure 4 it can be observed that the maximum concentration 
of antineoplastics studied was obtained from the first col-
lection time (15 minutes), as expected for an intravenous 
infusion. For DOX, a kinetic curve was not constructed 
since the plasma concentration was only quantified at the 
first timepoint collection.
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CONCLUSIONS
In the present study, an LLE-HPLC-DAD method 
for the simultaneous analysis of four chemically and struc-
turally different antineoplastic drugs was developed. This 
method is simple, fast and presented values of linearity, 
robustness, precision and efficiency of extraction in the 
range evaluated. Thus, the features of the proposed method 
to determine the antineoplastic agents fluorouracil, ifosfa-
mide and cyclophosphamide in plasma, i.e., good analyti-
cal performance, simplicity and low cost of the technique, 
make this approach very convenient for application in 
therapeutic drug monitoring and pharmacokinetic studies. 
And, for doxorubicin, it can be applied in the diagnosis 
of poisoning, since it can detect/quantify concentrations 
above the therapeutic range.
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